| Background and Introduction

Over the past decades, liquid biopsy techniques have emerged as viable alternatives to the analysis of traditional tissue biopsy samples. Circulating tumour DNA (ctDNA) is part of total cell free DNA found mainly in plasma, and act as biomarkers for cancer companion diagnostics and treatment. However, due to the low fraction of ctDNA in clinical samples, inaccurate results may also occur and might not be able to precisely reflect the tumour burdens.

GeneWell developed a series of patient-like reference standards to help with the verification of assay sensitivity and performance, as well as reference material with ultra low allelic frequency for MRD testings. These ctDNA reference standards are derived from human tumor cell lines and fragmented, which ensure the most patient-like ctDNA sizing and clinically-relevant genomic backgrounds. They are ideal materials for assay development, performance validation and LoD detection, as well as routine quality control for high-sensitivity NGS and PCR assays. 

| Key Features

● Cell line-derived products to better mimic clinical patient samples 

● Fragmented to around 160bp, similar to the nature of cell-free DNA (cfDNA)

● A wide range of allelic frequencies are offered with cancer-related variants, as well as matched wildtype

● Variants are precisely verified by ddPCR with multiple repeats, especially for  those with low AFs

● Multi fragmentation methods are also available upon requests

| Product List